Metabolic imaging predicts neoadjuvant therapy response before pancreatic cancer surgery

The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.The findings, published in JNCCN — Journal of the National Comprehensive Cancer Network — may help guide decisions on whether to proceed with complex surgery, continue current treatment or consider a chemotherapy switch, researchers noted.Anatomic imaging with CT or MRI poorly predicts response to neoadjuvant therapy among patients with borderlineRead More

Generated by Feedzy